DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Becker muscular dystrophy — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBecker muscular dystrophy maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for becker muscular dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
plakophilin 2 (PKP2) — PKP2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3TT9 · 1.55 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The 2015 review notes that nearly 30 years of research following the identification of dystrophin have led to dystrophin-dependent and -independent therapies that are close to or in human clinical trials, but it does not report any completed trial results for Becker muscular dystrophy. The 2019 paper explains that Becker muscular dystrophy is milder than Duchenne because mutations maintain the reading frame, allowing production of truncated dystrophin. It describes exon skipping therapy with antisense oligonucleotides as a strategy to restore the reading frame and convert a severe Duchenne phenotype to a mild one, but again provides no patient outcome data for Becker.
The 1996 abstract states bluntly that despite over 20 years of research, corticosteroids remained the only available pharmacological treatment for Duchenne muscular dystrophy, and that effective treatment would require dystrophin restitution in skeletal, cardiac, smooth muscle and nonmuscle tissues. It mentions that emerging biological, molecular and small molecule therapeutics were showing promise, but gives no numbers for Becker patients.
No abstract reports survival, response rates, or sample sizes for any drug tested specifically in Becker muscular dystrophy. The evidence consists of reviews describing therapeutic strategies and the underlying genetics, not completed clinical trials. What is still missing are dedicated clinical trials in Becker patients with clearly defined endpoints, adequate funding for such trials, and patient stratification by specific mutation type.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Annual Review of Genomics and Human Genetics · 2015 · 300 citations · open access
The Pathogenesis and Therapy of Muscular Dystrophies
AbstractCurrent molecular genomic approaches to human genetic disorders have led to an explosion in the identification of the genes and their encoded proteins responsible for these disorders. The identification of the gene altered by mutations in Duchenne and Becker muscular dystrophy was one of the earliest examples of this paradigm. The nearly 30 years of research partly outlined here exemplifies the road that similar current gene discovery protocols will be expected to travel, albeit much more rapidly owing to improved diagnosis of genetic disorders and an understanding of the spectrum of mutations thought to cause them. The identification of the protein dystrophin has led to a new understanding of the muscle cell membrane and the proteins involved in membrane stability, as well as new candidate genes for additional forms of muscular dystrophy. Animal models identified with naturally occurring mutations and developed by genetic manipulation have furthered the understanding of disease progression and underlying pathology. The biochemistry and molecular analysis of patient samples have led to the different dystrophin-dependent and -independent therapies that are currently close to or in human clinical trials. The lessons learned from decades of research on dystrophin have benefited the field of human genetics.
Journal of Personalized Medicine · 2019 · 41 citations · open access
Mutation-Based Therapeutic Strategies for Duchenne Muscular Dystrophy: From Genetic Diagnosis to Therapy
AbstractDuchenne and Becker muscular dystrophy (DMD/BMD) are X-linked muscle disorders caused by mutations of the DMD gene, which encodes the subsarcolemmal protein dystrophin. In DMD, dystrophin is not expressed due to a disruption in the reading frame of the DMD gene, resulting in a severe phenotype. Becker muscular dystrophy exhibits a milder phenotype, having mutations that maintain the reading frame and allow for the production of truncated dystrophin. To date, various therapeutic approaches for DMD have been extensively developed. However, the pathomechanism is quite complex despite it being a single gene disorder, and dystrophin is expressed not only in a large amount of skeletal muscle but also in cardiac, vascular, intestinal smooth muscle, and nervous system tissue. Thus, the most appropriate therapy would be complementation or restoration of dystrophin expression, such as gene therapy using viral vectors, readthrough therapy, or exon skipping therapy. Among them, exon skipping therapy with antisense oligonucleotides can restore the reading frame and yield the conversion of a severe phenotype to one that is mild. In this paper, I present the significance of molecular diagnosis and the development of mutation-based therapeutic strategies to complement or restore dystrophin expression.
The Application of Clinical Genetics · 1996 · 5 citations
Doing Academic Planning: Effective Tools for Decision Making.
AbstractThe identification of dystrophin and the causative role of mutations in this gene in Duchenne and Becker muscular dystrophies (D/BMD) was expected to lead to timely development of effective therapies. Despite over 20 years of research, corticosteroids remain the only available pharmacological treatment for DMD, although significant benefits and extended life have resulted from advances in the clinical care and management of DMD individuals. Effective treatment of DMD will require dystrophin restitution in skeletal, cardiac, and smooth muscles and nonmuscle tissues; however, modulation of muscle loss and regeneration has the potential to play an important role in altering the natural history of DMD, particularly in combination with other treatments. Emerging biological, molecular, and small molecule therapeutics are showing promise in ameliorating this devastating disease, and it is anticipated that regulatory environments will need to display some flexibility in order to accommodate the new treatment paradigms.
Expert Opinion on Orphan Drugs · 2015 · 1 citations
Investigational treatments and therapeutic targets in Becker muscular dystrophy
AbstractIntroduction: Becker muscular dystrophy (BMD) is a progressive X-linked muscle-wasting disease caused by mutations in the dystrophin gene. Duchenne muscular dystrophy (DMD) is also caused by such mutations but shows rapidly progressive muscle wasting. Therefore, studies aimed at establishing treatments have been focused on DMD. Fortunately, most DMD treatments can also be applied as BMD treatments because of the common pathophysiology. Although the natural history of BMD is very heterogeneous, this is a debilitating disease with progressive muscle weakness. Thus, treatments for BMD are urgently needed.Areas covered: Treatments for BMD are described by reviewing treatments for DMD, as BMD and DMD share a common pathophysiology caused by dystrophin abnormalities. Additionally, the characteristics of BMD patients aged over 60 years are summarized.Expert opinion: Until now, many efforts have been made to establish treatments for DMD, while efforts toward BMD treatments have not been prominent. It is now time to make more effort to establish BMD treatments, especially with regard to modulation of splicing in BMD-specific mutations. Although most DMD treatments can be applied as BMD treatments, it must be remembered that some BMD patients are able to live a near-normal life even with a mutation in the dystrophin gene.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
